TRxADE HEALTH, Inc. (MEDS) Income Statement
MEDS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsMEDS revenue and net income
Where MEDS's revenue goes
2025Each bar shows an amount and its share of revenue. MEDS kept −433.9% of revenue as net income.
MEDS profit margins
MEDS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +28.7% | −10.7% | — | — |
| Gross profit | −645.3% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
MEDS quarterly EPS vs estimates
Next report: November 18, 2026.
MEDS income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $23.3M | $18.1M | $0 | $32.8M |
| Cost of revenue | $33.0M | $16.4M | $0 | $27.0M |
| Gross profit | −$9.6M | $1.8M | $0 | $5.7M |
| Research & development | — | — | $375 | $1,400 |
| Sales, general & admin | $71.6M | $6.8M | $2.9M | $7.1M |
| Total operating expenses | $71.6M | $7.9M | $2.9M | $9.2M |
| Operating income | −$81.2M | −$6.1M | −$2.9M | −$3.4M |
| Interest expense | $4.6M | $831,467 | $15,081 | $287,183 |
| Income before taxes | −$101.3M | −$6.9M | −$2.9M | −$2.7M |
| Net income | −$101.3M | −$6.9M | −$2.9M | −$2.7M |
| EBITDA | −$93.5M | −$4.9M | −$2.9M | −$369,034 |
| EPS (diluted) | −$64.60 | −$6.60 | −$3.09 | — |
| Gross margin | −41.3% | 9.7% | — | 17.5% |
| Operating margin | −347.9% | −33.9% | — | −10.4% |
| Net margin | −433.9% | −37.8% | — | −8.4% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8M | $1.6M | $1.7M | $3.0M | $7.8M | $10.9M | $12.4M | $5.7M | $10.4M | $7.9M | $34.4M | $0 |
| Cost of revenue | $2.0M | $1.4M | $11.9M | $2.8M | $7.3M | $10.2M | $11.8M | $5.6M | $9.0M | $7.1M | $31.6M | — |
| Gross profit | −$174,393 | $170,221 | −$10.3M | $231,012 | $505,752 | $692,641 | $601,437 | $53,820 | $1.4M | $820,108 | $2.8M | — |
| Sales, general & admin | $7.2M | $5.8M | $4.1M | $31.0M | $5.2M | $31.2M | $666,075 | $2.5M | $1.8M | $1.8M | $8.3M | $903,312 |
| Total operating expenses | $7.2M | $6.2M | $2.5M | $31.8M | $6.0M | $32.0M | $4.3M | $1.8M | $3.7M | $2.3M | $13.1M | $903,312 |
| Operating income | −$7.3M | −$6.0M | −$12.8M | −$31.5M | −$5.5M | −$31.3M | −$3.7M | −$1.7M | −$2.3M | −$1.5M | −$10.3M | −$903,312 |
| Interest expense | $1.6M | $2.1M | $875,719 | $1.4M | $1.2M | $1.1M | $689,186 | $137,614 | $518,260 | $299,030 | $1.6M | — |
| Income before taxes | −$18.4M | −$7.7M | −$27.9M | −$34.3M | −$6.7M | −$32.4M | −$4.3M | −$1.9M | −$2.4M | −$1.8M | −$11.8M | −$903,312 |
| Net income | −$18.4M | −$7.7M | −$27.9M | −$34.3M | −$6.7M | −$32.4M | −$4.3M | −$1.9M | −$2.4M | −$1.8M | −$11.8M | −$903,312 |
| EBITDA | −$7.0M | −$5.3M | −$12.0M | −$32.1M | −$4.7M | −$30.5M | −$3.1M | −$1.3M | −$11,891 | −$1.0M | −$5.4M | −$903,312 |
| EPS (diluted) | −$3.26 | −$3.24 | −$13.75 | −$19.18 | −$5.28 | −$26.38 | — | — | — | — | — | — |
| Gross margin | −9.8% | 10.9% | −614.4% | 7.7% | 6.5% | 6.4% | 4.8% | 0.9% | 13.4% | 10.3% | 8.1% | — |
| Operating margin | −412.7% | −385.7% | −766.0% | −1,047.1% | −70.6% | −288.6% | −30.2% | −30.8% | −21.9% | −18.7% | −30.0% | — |
| Net margin | −1,031.7% | −496.5% | −1,667.2% | −1,139.0% | −85.6% | −298.5% | −34.9% | −32.9% | −22.8% | −22.4% | −34.3% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in MEDS's financial statements (latest annual report filed March 20, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
MEDS financial results
In fiscal year 2025 (ended December 31, 2025), TRxADE HEALTH reported revenue of $23.3 million, up 28.7% from the year before. It had a net loss of $101.3 million, a net profit margin of −433.9%. Diluted earnings per share came to −$64.60.
See the MEDS stock overview for the latest quote and news, or the MEDS chart for price history and technical indicators.
MEDS income statement FAQ
What is TRxADE HEALTH's annual revenue?
TRxADE HEALTH reported total revenue of $23.3 million for fiscal year 2025, which ended on December 31, 2025. That was up 28.7% from $18.1 million the previous year.
Is TRxADE HEALTH profitable?
No. TRxADE HEALTH reported a net loss of $101.3 million in fiscal 2025, a net profit margin of −433.9%; its operating margin was −347.9%.
What is TRxADE HEALTH's gross margin?
TRxADE HEALTH's gross margin was −41.3% in fiscal 2025: for every $100 of revenue, TRxADE HEALTH kept $-41 after the direct cost of its products and services.
What are TRxADE HEALTH's earnings per share?
TRxADE HEALTH earned $-64.60 per diluted share in fiscal 2025, compared with $-6.60 a year earlier.
When will TRxADE HEALTH report its next earnings?
TRxADE HEALTH is expected to report results for the quarter ending September 30, 2026 on November 18, 2026.
When does TRxADE HEALTH's fiscal year end?
TRxADE HEALTH's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 20, 2026.